MK-677 (Ibutamoren) Geriatric (65+) Caregiver Administration Guidance

What Is MK-677 and Why Is It Used in Older Adults?

MK-677 is a non-peptide, orally active ghrelin receptor agonist that stimulates the pituitary to release growth hormone (GH) and raises circulating IGF-1 levels. Adults over 65 experience roughly a 14% decline in GH secretion per decade after age 30, contributing to sarcopenia, reduced bone density, and impaired recovery from illness. MK-677 addresses this mechanism directly without requiring daily injections, which makes it practical for caregiver-managed administration.

How It Works

The drug binds the growth hormone secretagogue receptor 1a (GHSR-1a), mimicking endogenous ghrelin. A single oral dose of 25 mg raises mean 24-hour GH levels from approximately 0.6 ng/mL at baseline to 2.4 ng/mL, and serum IGF-1 increases by 40 to 60% within two weeks of daily dosing, based on data from the key 12-month trial by Nass et al. Published in the Annals of Internal Medicine [1].

The Evidence Base for Geriatric Use

The most frequently cited controlled trial enrolled 65 adults aged 60 to 81 years and randomized them to 25 mg MK-677 or placebo for 12 months. Fat-free mass increased by 1.67 kg in the treated group versus a 0.24 kg loss in the placebo group (P<0.05). IGF-1 rose to young-adult levels in the treated cohort. Investigators noted that the drug was "well tolerated" but that "minor lower-extremity edema and muscle pain occurred more frequently" in treated participants [1]. A separate 2-year extension of an earlier MK-677 trial in older men and women confirmed sustained IGF-1 elevation without tachyphylaxis [2].

Caregiver Responsibilities Before the First Dose

Caregivers are not just pill dispensers. Before giving the first dose, you must confirm that the prescriber has reviewed three specific items.

Baseline Labs Required

The prescriber should have on file:

• Fasting glucose and HbA1c (MK-677 can impair insulin sensitivity)
• Serum IGF-1 (to confirm deficiency and establish a baseline)
• Basic metabolic panel (to screen for fluid-retention risk)
• A current medication list reviewed for drug interactions

The American Association of Clinical Endocrinology (AACE) recommends confirming IGF-1 deficiency before initiating GH-axis therapies in older adults, and this principle applies to secretagogues as well [3].

Confirming the Compounded Preparation

MK-677 is not FDA-approved as a finished pharmaceutical product. It is dispensed through compounding pharmacies that prepare it as oral capsules or a liquid suspension. The FDA has flagged unapproved growth hormone secretagogues in warning letters to compounders, and caregivers should verify the dispensing pharmacy holds a valid 503A or 503B accreditation before accepting any supply [4]. Capsules from non-accredited sources carry unknown purity and potency.

Informed Consent Documentation

The prescriber should have documented that the older adult (or their legal health-care proxy) understands MK-677 is off-label, investigational for this indication, and not covered by Medicare Part D in most formularies.

Dosing Protocol for Adults Aged 65 and Older

Geriatric pharmacology differs from standard adult dosing. Renal clearance declines by about 1% per year after age 40, hepatic first-pass metabolism slows, and volume of distribution changes with body composition shifts [5].

Starting Dose

Begin at 10 mg orally once nightly. The bedtime schedule takes advantage of the physiological GH pulse that normally occurs during slow-wave sleep; dosing at that time augments rather than disrupts the endogenous rhythm. A 10 mg starting dose is half the dose used in the Nass trial but reduces early fluid retention risk in a population already prone to lower-extremity edema.

Titration Schedule

| Week | Dose | Caregiver action | |------|------|-----------------| | 1 to 4 | 10 mg nightly | Record morning fasting glucose 3x/week | | 5 to 8 | 15 mg nightly (if glucose stable) | Check weight weekly, note ankle edema | | 9 to 12 | 20 to 25 mg nightly (if tolerating well) | Recheck IGF-1 and HbA1c at week 12 |

Do not increase the dose if fasting glucose has risen more than 15 mg/dL above baseline or if ankle circumference has increased by more than 1 cm.

Dose for Adults With Pre-existing Type 2 Diabetes

Adults with type 2 diabetes were underrepresented in MK-677 trials. A 2008 study by Svensson et al. In the Journal of Clinical Endocrinology and Metabolism showed that 2 weeks of MK-677 at 25 mg/day increased fasting glucose by approximately 0.3 mmol/L and reduced insulin sensitivity index by 20% in healthy older adults [6]. In diabetic patients on insulin or sulfonylureas, the prescriber should reduce the secretagogue or adjust diabetes medications before initiating. Caregivers managing a diabetic patient should check fasting glucose every morning for the first 30 days.

Administration Technique

Oral Capsules

1. Give the capsule with 4 to 8 oz of water at bedtime.
2. The patient should sit upright for at least 10 minutes after swallowing.
3. Food does not significantly affect bioavailability; the dose can be given with a light snack if the patient experiences nausea.
4. Never crush the capsule unless the compounding pharmacy explicitly states the formulation is crushable. Some modified-release preparations will deliver the entire dose at once if disrupted.

Liquid Suspension (if dispensed)

Liquid MK-677 is sometimes prepared at 10 mg/mL or 25 mg/mL concentrations. Use only the oral syringe provided by the pharmacy. Draw to the prescribed mark, administer sublingually or swallow directly, then rinse the syringe with warm water. Do not mix into beverages; some formulations are pH-sensitive.

Missed Dose Protocol

If a dose is missed and it is still within 4 hours of the scheduled bedtime, give the dose. If more than 4 hours have passed, skip that dose entirely and resume the next night. Do not double-dose. IGF-1 has a half-life of approximately 15 hours, so a single missed dose does not produce meaningful clinical loss [7].

Monitoring: What Caregivers Track at Home

Consistent home monitoring is what separates safe geriatric use from preventable adverse events. Keep a written log that the prescriber reviews at each telehealth visit.

Weekly Caregiver Log Items

• Body weight (same scale, same time of day, before breakfast)
• Fasting blood glucose (fingerstick or CGM download)
• Ankle circumference or presence of pitting edema (press the inner ankle for 5 seconds; record 0 to 3+ grading)
• Sleep quality (the patient's self-report; MK-677 is associated with more vivid dreams)
• Appetite level (increased appetite is expected; document if caloric intake changes significantly)

Lab Schedule

| Timepoint | Tests | |-----------|-------| | Baseline | IGF-1, HbA1c, fasting glucose, CMP | | Week 6 | Fasting glucose, weight, edema assessment | | Month 3 | IGF-1, HbA1c, fasting glucose, CMP | | Month 6 | IGF-1, HbA1c, fasting glucose, CMP | | Annually | Full metabolic panel, bone density if clinically indicated |

The target IGF-1 range for adults aged 65 to 80 is approximately 100 to 200 ng/mL by most reference laboratory norms. IGF-1 above 300 ng/mL warrants dose reduction [8].

Drug Interactions Relevant to the Geriatric Population

Older adults take an average of 5.6 prescription medications [9]. MK-677 interacts with several drug classes common in this age group.

Insulin and Oral Hypoglycemics

As noted above, MK-677 reduces insulin sensitivity. Caregivers managing a patient on insulin glargine, insulin detemir, or sulfonylureas (e.g., glipizide, glyburide) should alert the prescriber before the first MK-677 dose so adjustments can be made proactively. A study in Diabetes Care confirmed that elevated GH levels antagonize insulin action at the receptor level, a mechanism directly relevant to MK-677's mechanism [10].

Corticosteroids

Systemic corticosteroids (prednisone, methylprednisolone) blunt GH secretion and may reduce MK-677 efficacy. They also independently raise blood glucose. Concurrent use requires more frequent glucose monitoring.

CYP3A4 Substrates

MK-677 is metabolized partly via CYP3A4. Medications that strongly inhibit CYP3A4, including clarithromycin, ketoconazole, and ritonavir, may raise MK-677 plasma levels unpredictably. Caregivers should notify the prescriber any time an antibiotic or antifungal is started or stopped.

Recognizing and Managing Side Effects in Older Adults

Peripheral Edema

Fluid retention is the most common adverse effect, occurring in roughly 25 to 30% of older adults in the Nass trial [1]. Grade the edema at each weekly check. Mild edema (1+, pitting resolves in <15 seconds) can be managed with sodium restriction and leg elevation. Moderate edema (2+) warrants a call to the prescriber within 24 hours. Severe edema (3+ or new shortness of breath) is a stop-the-drug emergency.

Increased Appetite and Weight Gain

MK-677 activates the same receptor as ghrelin, an appetite-stimulating hormone. Patients may request food more often or at unusual hours, which caregivers should anticipate rather than suppress. Channeling increased appetite toward protein-rich foods (minimum 1.2 g/kg/day is the AACE recommendation for sarcopenic older adults) [3] captures therapeutic benefit while minimizing fat mass gain.

Insulin Resistance and Hyperglycemia

A fasting glucose rise above 126 mg/dL on two consecutive mornings is the threshold for contacting the prescriber the same day. This matches the American Diabetes Association diagnostic criterion for diabetes, and any crossing of that line during MK-677 therapy should prompt a medication review [11].

Muscle Pain and Fatigue

Mild myalgia occurs in a subset of patients as IGF-1 rises rapidly in the first 4 to 6 weeks. This typically resolves without intervention. Persistent or severe muscle pain warrants a creatine kinase measurement to rule out drug-related myopathy.

Joint Discomfort

Elevated GH and IGF-1 can cause water retention in joint spaces, producing carpal tunnel-like symptoms or knee stiffness. These effects are dose-dependent and usually resolve with a dose reduction from 25 mg to 15 mg.

When to Stop MK-677 and Contact the Prescriber Immediately

Stop the drug and call the prescriber the same day if:

• Fasting glucose exceeds 200 mg/dL on any single reading
• The patient develops new-onset peripheral edema above 2+
• Breast tissue enlargement (gynecomastia) appears
• Any new lump, mass, or unexplained weight loss occurs (MK-677 raises IGF-1, and elevated IGF-1 is associated with increased risk of certain cancers; active malignancy is a contraindication) [12]
• The patient reports chest pain, sudden shortness of breath, or new confusion

Special Considerations for Cognitively Impaired Older Adults

Caregivers managing patients with mild cognitive impairment or dementia face additional challenges with any oral medication regimen.

Swallowing Safety

Dysphagia affects up to 47% of nursing-home residents [13]. Before starting MK-677 in a patient with known swallowing difficulties, ask the prescriber whether a liquid formulation is appropriate and whether a speech-language pathology swallow evaluation should precede initiation.

Adherence Documentation

Cognitively impaired patients cannot reliably self-report whether they took a dose. Caregivers should use a dated pill log or blister pack with daily tracking. Electronic pill dispensers with caregiver alerts are an effective tool for this population.

Assent and Surrogate Decision-Making

Where the older adult lacks decision-making capacity, a legally authorized representative (health-care proxy, durable power of attorney for health care, or court-appointed guardian) must provide written consent before therapy begins. The prescriber should confirm this documentation is in the chart before writing the compounding prescription.

Caregiver Communication With the Prescribing Clinician

Telehealth platforms make it practical for caregivers to report data between scheduled visits. Use this framework for every communication:

1. Identify the patient and current dose ("Mrs. Chen, 78F, currently on MK-677 10 mg nightly, day 22 of therapy").
2. State the specific concern with a number ("Fasting glucose this morning 142 mg/dL, up from baseline of 98 mg/dL").
3. Report any concurrent changes ("She started clarithromycin 500 mg BID for a sinus infection on day 18").
4. Ask a direct yes/no or choice question ("Should I hold tonight's dose pending your review?").

This structured format mirrors SBAR (Situation, Background, Assessment, Recommendation) communication standards endorsed by the Joint Commission and reduces response delays [14].

Storage and Handling

Oral MK-677 capsules from a 503A compounding pharmacy are typically dispensed with a beyond-use date of 180 days when stored at controlled room temperature (68 to 77°F / 20 to 25°C). Key storage rules:

• Keep away from direct light and moisture.
• Do not store in a bathroom medicine cabinet (humidity degrades many compounded preparations).
• If using a liquid suspension, most formulations require refrigeration at 36 to 46°F (2 to 8°C) and carry a 90-day beyond-use date.
• Discard any preparation that changes color, develops particulate matter, or passes its beyond-use date.
• Keep out of reach of other household members. MK-677 is not appropriate for adults under 18 or for individuals without an active prescriber relationship.